



1720

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Burke T. BARRETT et al.
 Application No.: 10/612,683
 Filed: July 1, 2003
 For: TREATMENT OF OBESITY BY BILATERAL VAGUS NERVE STIMULATION

Group Art Unit: 3762
 Confirmation No. 3429
 Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450


Sir:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicant(s) wish to make of record the references listed on the attached form PTO/SB/08 (substitute for PTO-1449). Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references. [Copies of the listed references were cited and/or filed in the parent application, U.S. Parent No. 6,587,719 issued July 1, 2003.]

- This Information Disclosure Statement is being filed (a) within three months of the filing date of the subject patent application, OR (b) before the mailing date of a first Office Action on the merits. No certification or fee is required.
- This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement. No fee is required.
 - No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement. No fee is required.
 - A check in the amount of \$180.00 is enclosed under 37 CFR §1.17(p).
- This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. A check in the amount of \$180.00 is enclosed under 37 CFR §1.17(p).
 - Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement.
 - No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Blank Rome LLP
 600 New Hampshire Avenue, N.W.
 Washington, DC 20037
 Tel: (202) 772-5800
 Fax (202) 572-8398
 Customer No.: 27557
 Date: August 17, 2005


 Michael D. White
 Attorney of Record
 Registration No. 32,795



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of 3

Complete if Known

Application Number	10/612,683
Filing Date	July 1, 2003
First Named Inventor	Burke T. BARRETT et al.
Art Unit	3429
Examiner Name	Unassigned
Attorney Docket Number	001301.00356

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/612,683
Filing Date	July 1, 2003
First Named Inventor	Burke T. BARRETT et al.
Art Unit	3762
Examiner Name	Unassigned
Attorney Docket Number	001301.00356

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Iggo, A., Gastric Mucosal Chemoreceptors with Vagal Afferent Fibres etc., Univ. of Edinburgh (1957), 398-409.
		Stacher, G. et al., Cholecystokinin Decreases Appetite and Activation etc., Brain Research Pub. (1979), 325-331.
		Rohner-Jeanrenaud, F. et al., A Role for the Vagus Nerve in the Etiology etc., Int'l. J. Obesity (1985), 71-75.
		Hoebel, B., Brain Neurotransmitters in Food and Drug Reward, AM. J. Clin. Nutr 42 (1985), 1133-1150.
		Foltin, R. et al., Food Intake in Baboons: Effects of Long-Acting Cholecystokinin Analog, Appetite (1989), 145-152.
		Moran, T. et al., "Potent and Sustained Satiety Actions of Cholecystokinin etc., Am. J. Clin. Nutr 55 (1992), 286S-90S.
		Moran, T. et al., Blockade of Type A, But Not Type B, CCK Receptors etc., Am. Physiol. Soc. (1993), R620-R624.
		Esfahani, N. et al., Inhibition of Serotonin Synthesis Attenuates etc., Pharmac Biochem Behavior 51 (1995), 9-12.
		Levin, B. et al., Role of the Brain in Energy Balance and Obesity, Am. J. Physiol. 271 (1996), R491-\$500.
		Pierson, M., Synthesis and Biological Evaluation of Potent etc., J. Med. Chem. 40 (1997), 4302-4307.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/612,683
Filing Date	July 1, 2003
First Named Inventor	Burke T. BARRETT et al.
Art Unit	3762
Examiner Name	Unassigned
Attorney Docket Number	001301.00356

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Brownell, K. et al., ed., Eating Disorders and Obesity, Guilford Press (), 3-7.	
		Ritter, S. et al., ed., Neuroanatomy and Physiology of Abdominal Vagal Afferents, CRC Press (), 221-248.	
		Matson, C. et al., Long-Term CCK-Leptin Synergy Suggests Role for CCK etc., Am. J. Physiol. 276 (1999), R1038-45.	
		Edmond, M. et al., Central Leptin Modulates Behavioral/Neural Responsivity etc., Am. J. Physiol. 276 (1999), R1545-49.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.